ArticleEndocrine2026
Thyroid cancer and thyroid nodules in acromegaly: a single-center retrospective study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeTo evaluate the incidence and progression of thyroid nodules and cancers in acromegaly and the necessity for increased surveillance.
methodsThis retrospective study identified 1075 acromegaly patients who underwent thyroid ultrasounds from 1830 consecutive cases between 2013 and 2022 at a single center. Thyroid nodules were assessed using the American College of Radiology Thyroid Imaging Reporting and Data System. Control data were from 17839 individuals who received thyroid ultrasounds at a health screening center during the same period.
resultsIn 1830 acromegaly patients, 80 thyroid cancers (4.4, 82.5% females) were reported, mainly papillary, except 1 follicular and 1 medullary cancer. Thyroid nodules were found in 765 (71.2%) acromegaly patients at baseline, more than in the control (43.7%, p < 0.001). Nodule size in acromegaly was slightly larger (0.7 [0.5, 1.2] vs. 0.5 [0.4, 0.9]cm, p < 0.001). During a 3.9 ± 2.6-year follow-up, new thyroid cancers in acromegaly were mainly confirmed in previously high-risk nodules. Among 339 acromegaly patients with follow-up ultrasound, 57 (16.8%) confirmed new thyroid cancers or nodular growth over 2.8 ± 2.3 years, compared to 10.8% (302/2796) in controls with a shorter follow-up (1.0 [0.9,1.1] years). During this short interval, no difference in growth hormone or insulin-like growth factor 1 levels was observed in acromegaly patients with newly diagnosed thyroid cancers.
conclusionThyroid nodules are more common in acromegaly, but whether thyroid cancer risk is increased remains uncertain. Given the potential overdiagnosis, our data do not support routine baseline thyroid ultrasound screening, and thyroid nodule surveillance may follow risk-stratified recommendations in the general population.
Indexed as
Identifiers
41801513What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.